Global Engage is pleased to announce the Novel Antibody Therapeutics Congress one of five meetings in our Research & Technology Series.
With recent breakthroughs in immunotherapeutics, biotherapeutics are set to lead the way in oncology in the coming years. As one of the dominant biologic formats, monoclonal antibodies stand ready to capitalise on this, building on two decades offered of exciting advancements in the treatment of cancer.
Designed for experts in pharma and academia, this conference will explore the latest advances in antibody-based therapeutics in oncology. Talks will review the recent developments in bispecific antibody technology, as well as exploring the potential of new antibody and antibody-mimicking formats. A dedicated checkpoint blockades session will also examine new approaches in neutralizing cancer cell immune blockades, including advances in PD1, PD-L1 and CTLA4 targeting therapeutics, and the discovery and targeting of new biomarkers
The Novel Antibody Therapeutics Congress one of five co-located conferences exploring key areas in immuno-oncology. The Research & Technology Series will attract over 100 speakers and 350+ attendees. These interactive meetings provide the opportunity to keep up to date with the cutting edge of research and make connections with industry experts, researchers, investors and businesses.